Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-11 pm EST			5-day change	1st Jan Change
172.50 ^USD	-2.84%		-5.21%	+12.80%

Dec. 10	This Is Decision Day
Dec. 10	Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating	MT

Transcript : Biogen Inc., Q2 2024 Earnings Call, Aug 01, 2024

Published on 08/01/2024 at 08:30 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning. My name is Anna, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Biogen Inc.

Dec. 10	This Is Decision Day
Dec. 10	Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating	MT
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 10	HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144	MT
Dec. 05	Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	CI
Dec. 05	Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	RE
Dec. 05	Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen	RE
Dec. 04	Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option	MT
Dec. 03	Eisai Co., Ltd. and Biogen Inc. Present New Data	CI
Dec. 03	Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	RE
Dec. 03	Health Care Up on Alzheimer's Hopes - Health Care Roundup	DJ
Dec. 03	Biogen Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 11:30 AM
Dec. 02	Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference	MT
Dec. 02	Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025	CI
Dec. 02	Biogen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 12:55 PM
Dec. 01	Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	CI
Nov. 28	Sector Update: Health Care Stocks Mixed Premarket Friday	MT
Nov. 28	Sector Update: Health Care	MT
Nov. 28	Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection	MT
Nov. 28	Jefferies Adjusts Price Target on Biogen to $210 From $190, Maintains Buy Rating	MT
Nov. 28	Eisai Announces New Drug Application for Subcutaneous Formulation of Leqembi Subcutaneous Formulation Ofleqembi Subcutaneous Form Formulation of Leqemab	CI
Nov. 27	Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI	CI
Nov. 25	Biogen, Eisai Submit Supplemental Biologics License Application to FDA for Weekly Lecanemab Injections	MT
Nov. 25	Eisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik?? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status	CI
Nov. 24	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT